Press Release

Printer Friendly Version View printer-friendly version
<< Back
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call

WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 19, 2018-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will release fourth quarter and full year 2017 financial results on Monday, March 26, 2018. Kala will host a live conference call and webcast at 8:00 AM ET to provide a general business update and discuss the Company’s 2017 financial results.

The dial-in numbers to access the conference call are 866-300-4091 for domestic callers and 703-736-7433 for international callers. The conference ID is 7082747. To access a live webcast and subsequent archived recording of the call, please visit the “Investors & Media” section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

Source: Kala Pharmaceuticals, Inc.

Investors and Media:
MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
cduong@macbiocom.com